clinical trial · NCT07121829
Tovorafenib (DAY101) or in Combination With Pimasertib for Participants With Melanoma and Other Solid Tumors
MelanomaSolid TumorPilocytic AstrocytomaNon Small Cell Lung CancerColorectal CancerPancreatic CancerMAP Kinase Family Gene MutationRAS MutationTovorafenibTovorafenib Drug: Pimasertib
brief summary
This is a subprotocol of Master Protocol DAY101-102 and is a Phase 1b/2, multi-center, open label subprotocol of participants ≥12 years of age, with recurrent or progressive solid tumors with alterations in the key proteins of the MAPK pathway, such as tumors that harbor RAS or RAF alterations. \*Note: Study concluded as Phase 1b only.
started
May 2, 2022
primary completion
Dec 18, 2024
completion
Dec 18, 2024
last updated
Aug 14, 2025
official title
A Phase 1b/2, Subprotocol of DAY101 in Combination With Pimasertib for Patients With Recurrent, Progressive, or Refractory Solid Tumors and MAPK Pathway Aberrations
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol